▲ +182.90% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for SQZ Biotechnologies in the last 3 months. The average price target is $38.33, with a high forecast of $40.00 and a low forecast of $37.00. The average price target represents a 182.90% upside from the last price of $13.55.
The current consensus among 4 investment analysts is to buy stock in SQZ Biotechnologies.
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. The company's lead product candidate, SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.